Speaking Engagement

The New Patent Law in China – Significance for Life Sciences

Berkeley Center for Law & Technology

17 Nov 2020 04:30 p.m. - 06:00 p.m.

China’s commitment to have a patent linkage system, similar to the Hatch-Waxman regime in the United States, was an important outcome of the Phase 1 Trade Agreement between the US and China. On October 17, 2020 that commitment was realized through amendments to China’s patent law. Much uncertainty still remains about the roles of the courts, China’s food and drug agency, and China’s patent office in implementing this new system for linking pharmaceutical regulatory approval with patent infringement determinations. Join us and a world-class team of outside and in-house Chinese and US lawyers as we discuss the implications of China’s “patent linkage” regime for foreign and Chinese innovative pharmaceutical companies and generic competitors.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.